Scientific Research Publishing

Modern Plastic Surgery, 2026, 16(2), 62-69
https://www.scirp.org/journal/mps
ISSN Online: 2164-5280
ISSN Print: 2164-5213

Joseph E. Murray, Plastic Surgery, and the Birth of Modern Transplantation: A Historical and Scientific Review

Grant W. Carlson

Division of Plastic Surgery, Emory University School of Medicine, Atlanta, USA
Email: gcarlso@emory.edu

How to cite this paper: Carlson, G.W. (2026) Joseph E. Murray, Plastic Surgery, and the Birth of Modern Transplantation: A Historical and Scientific Review. *Modern Plastic Surgery*, **16**, 62-69.
https://doi.org/10.4236/mps.2026.162006

Received: January 3, 2026
Accepted: April 17, 2026
Published: April 20, 2026

Abstract

Joseph E. Murray's pioneering work in skin grafting and renal transplantation stands as one of the most consequential achievements in twentieth-century medicine. Although best remembered as a transplant surgeon and Nobel laureate, Murray's intellectual and technical foundations arose directly from plastic surgery—a specialty that, through its core principles of tissue handling, wound biology, and graft survival, provided the conceptual framework that made organ transplantation possible. The progression from wartime burn reconstruction, to the biological study of skin grafts, to the identical-twin renal transplants of the 1950s, represents one of modern surgery's most elegant translational arcs. This manuscript reviews the development of Murray's scientific ideas, the essential contributions of plastic surgery, the proof-of-principle skin graft on identical twins, and the ethical considerations that shaped the early days of organ transplantation. A detailed timeline is provided to contextualize the historical progression. The paper concludes by examining Murray's enduring influence on surgical science, medical ethics, and the emergence of transplantation as a clinical discipline.

Keywords

Skin Grafting, Allograft, Identical Twins, Azathioprine, Brain Death

1. Introduction

The evolution of organ transplantation is one of the defining stories of modern medicine. Before the mid-twentieth century, irreversible organ failure was universally fatal; the idea of replacing an organ from another human was largely confined to theoretical speculation. Between the 1940s and 1960s, this changed dra-

matically. Central to this transformation was Joseph E. Murray (1919-2012), a surgeon-scientist whose career bridged plastic surgery, immunobiology, and reconstructive principles [1].

Although Murray is best known for the 1954 identical-twin kidney transplant that earned him the 1990 Nobel Prize in Physiology or Medicine, his scientific grounding emerged from plastic surgery's foundational work on graft biology [2]. Plastic surgeons were the first to develop systematic nomenclature for tissue transfer—autograft, allograft, and xenograft—and to investigate the immunological factors determining graft survival. Murray's early exposure to burn reconstruction and skin grafting led him to appreciate that the biology of graft acceptance and rejection could extend far beyond the skin. From this insight emerged the scientific bridge that made organ transplantation possible.

This manuscript presents an integrated historical and scientific analysis of Murray's contributions, with particular attention to plastic surgery's role in the conceptual birth of transplantation.

2. Plastic Surgery as the Scientific Foundation

2.1. Skin Grafting and the Origins of Transplant Biology

Skin grafting was the first experimental model that illuminated the immune barriers to tissue transfer. Long before organ transplantation existed, plastic surgeons established that:

- Autografts are uniformly accepted.
- Allografts are predictably rejected.
- Repeat grafts from the same donor demonstrate accelerated rejection.

The skin is among the most antigenic tissues in the body due to its high density of antigen-presenting cells and constant immune surveillance, whereas the kidney elicits a comparatively less vigorous alloimmune response. These differences were critical in early transplantation research, where skin graft rejection served as a surrogate marker for histocompatibility.

The immunologic principles that made transplantation possible were elucidated in parallel by Peter Medawar through seminal skin-grafting experiments demonstrating that allograft rejection is immune-mediated and that immune tolerance can be acquired [3]. Although Medawar and Murray did not directly collaborate, their work converged conceptually through skin grafting as a shared experimental model. Medawar's laboratory studies defined the biological mechanisms of rejection and tolerance, while Murray applied these principles clinically, first by confirming permanent acceptance of skin grafts between identical twins and subsequently by performing the first successful renal transplantation. This translational bridge—from experimental skin grafting to curative organ transplantation—highlights the central role of plastic surgery in transforming immunologic theory into surgical reality.

These observations, made decades before modern immunology, laid the scientific groundwork for recognizing that transplantation was not merely a technical

problem but primarily a biological one.

The terminology—autograft, allograft, isograft, and later xenograft—was developed within plastic surgery to classify grafts by genetic relationship. Murray's intellectual training occurred in this environment. Skin grafting in burn patients, soldiers, and experimental settings served as the essential laboratory for his later work.

2.2. World War II and the Valley Forge General Hospital Experience

During World War II, Murray served at the U.S. Army's Valley Forge General Hospital, a center specializing in burn reconstruction [4]. Treating soldiers with devastating injuries, he observed a consistent biological pattern: autografts survived; homografts (allografts) initially appeared viable but succumbed to rejection.

These experiences sharpened his interest in the biological basis of graft survival. At Valley Forge, Murray saw more clinical grafts in two years than most civilian surgeons would encounter in a lifetime. The biological logic that would later make kidney transplantation feasible emerged directly from plastic surgical principles observed at the bedside.

2.3. The Proof of Principle: Identical Twins and Skin Grafts

Before attempting renal transplantation, Murray conducted a pivotal experiment: he performed a skin graft between identical twins to test whether their tissues behaved as autografts. The result—long-term graft survival without rejection—offered the essential biological proof that a kidney transplanted between identical twins might survive.

This step is often overshadowed in historical accounts but deserves emphasis. It was an elegant, plastic surgery-based strategy that:

1) Confirmed the biological premise.

2) Mitigated patient risk.

3) Demonstrated that the problem of rejection was immunologic, not surgical.

With this proof in hand, Murray and his colleagues at the Peter Bent Brigham Hospital attempted the first successful identical-twin kidney transplant in December 1954 [5]. The success of this operation transformed both surgical and medical science.

2.4. Development of Renal Transplantation at the Brigham

2.4.1. The Early Experimental Era (1950-1954)

Murray, Harrison, Merrill, and others began experimenting with renal transplantation in animal models and non-identical humans with terminal renal failure. These early efforts were unsuccessful due to rejection, but the failures reinforced the central insight: without immunosuppression or genetic identity, transplantation could not succeed.

2.4.2. The First Successful Kidney Transplant (1954)

On December 23, 1954, Murray performed the first lasting renal transplant between Ronald and Richard Herrick, identical twins [2]. The kidney functioned immediately and restored Richard to health. This landmark operation proved that transplantation could cure previously fatal disease.

2.4.3. Expansion Beyond Identical Twins

The challenge after 1954 was to extend transplantation to genetically non-identical donors. Over the next decade, Murray and his colleagues advanced:

- Total body irradiation [6]
- Early immunosuppressive regimens [7]
- The introduction of azathioprine, which finally enabled consistent survival.

These developments converted transplantation from an experimental endeavor into a reproducible therapy.

The transition from total body irradiation to pharmacologic immunosuppression represented a critical advance in transplantation. Early attempts to suppress rejection relied on irradiation to globally impair immune function, but this approach was limited by significant toxicity. A more precise strategy emerged with the development of antimetabolite drugs. Work by Gertrude B. Elion and George H. Hitchings led to the synthesis of 6-mercaptopurine, a purine analog that inhibits de novo nucleotide synthesis and thereby selectively impairs the proliferation of rapidly dividing cells, including activated lymphocytes [8]. This pharmacologic insight was translated into clinical transplantation through the development of azathioprine, a prodrug of 6-mercaptopurine, which provided more effective and sustained immunosuppression with reduced toxicity. The introduction of these agents enabled transplantation to move beyond genetically identical individuals by directly targeting the cellular mechanisms responsible for allograft rejection, transforming transplantation from an experimental procedure into a reproducible clinical therapy. This shift from nonspecific immune ablation to targeted pharmacologic modulation marked the true beginning of modern immunosuppressive therapy.

2.5. Ethical Foundations of Modern Transplantation

Joseph Murray's contributions to transplantation extended well beyond technical innovation and immunologic insight. He was among the first physicians to recognize that transplantation would succeed only if it developed within a clear ethical framework capable of sustaining public trust, protecting donors, and governing clinical practice. Long before bioethics emerged as a formal discipline, Murray confronted the moral implications of living donation and organ procurement as intrinsic components of surgical responsibility.

Murray's ethical reasoning arose directly from clinical experience. The 1954 identical-twin kidney transplant demonstrated that transplantation could cure otherwise fatal disease, but it also raised unprecedented questions: Is it permissible to expose a healthy donor to risk for the benefit of another? How should that risk

be defined and limited? And how could altruism be protected from coercion or commercial exploitation? Murray argued that living donation was ethically justifiable only when donor risk was minimal, fully understood, and freely accepted, and when recipient benefit was otherwise unattainable. These principles became the ethical cornerstone of living-donor transplantation.

As transplantation expanded beyond identical twins, Murray's ethical influence shifted from individual decision-making to institutional leadership. He understood that transplantation required shared standards, transparency, and collective oversight. In 1962, he chaired the First International Conference on Human Kidney Transplantation, which helped formalize donor selection criteria, recipient indications, and outcome reporting. At the Brigham, he served as medical director of the National Kidney Transplant Registry, recognizing that national data collection and outcome analysis were essential to responsible growth of the field. These efforts foreshadowed modern transplant governance systems, including UNOS and the SRTR.

Murray's ethical leadership culminated in his participation on the Harvard Ad Hoc Committee to Examine the Definition of Death in 1968 [9]. As the only surgeon on the committee, he brought a uniquely practical understanding of how evolving definitions of death intersected with organ donation, public trust, and medical responsibility. The committee's establishment of brain-death criteria—defined by unreceptivity and unresponsiveness, absence of brainstem reflexes, and apnea—provided the ethical and legal foundation for deceased-donor transplantation and remains one of the most consequential moments in modern medical ethics.

Throughout his career, Murray consistently warned that transplantation risked failure not from technical limitations, but from ethical erosion. He anticipated the dangers of organ commerce, inequitable access, and loss of public confidence, emphasizing that transplantation must remain grounded in altruism, scientific rigor, and societal consensus. In this sense, Murray was not only a pioneer of transplantation, but one of its earliest ethical architects, shaping the moral framework that continues to govern the field today.

2.6. Plastic Surgery, Transplantation, and the Surgeon-Scientist Identity

Murray exemplified the classical surgeon-scientist: someone who draws scientific insight from clinical observation, tests hypotheses experimentally, and then translates discoveries back to patient care.

Plastic surgery shaped this identity in three ways:

1) Technical mastery: gentle handling of tissues, vascular understanding, and grafting principles were essential to transplant success.

2) Biological literacy: plastic surgeons were among the first clinicians to link tissue survival to immunological compatibility.

3) Translational thinking: the move from skin graft to organ graft was a con-

ceptual leap rooted in reconstructive logic.

Murray's Nobel Prize was therefore not only a triumph for transplantation but an affirmation of plastic surgery's intellectual foundations.

2.7. Later Achievements and the Nobel Prize

In 1990, Joseph Murray and E. Donnall Thomas shared the Nobel Prize for their work in organ and bone marrow transplantation [10]. The Nobel Committee acknowledged that Murray's efforts established transplantation as a clinical discipline and that his early experiments created a new therapeutic paradigm.

Murray continued to practice plastic surgery throughout his career, becoming a respected leader in cleft lip and palate reconstruction, craniofacial surgery, and burn care. His dual legacy—reconstructive surgeon and transplant pioneer—remains unique in surgical history.

2.8. Emory's Connection and Transplantation Legacy

Murray's influence extended to major developments in immunosuppression at Emory University, where subsequent advances in transplant pharmacology and clinical protocols were realized. Emory later emerged as a leader in tacrolimus-based immunosuppression and advanced kidney and pancreas transplantation, reflecting a progression that can be traced to Murray's foundational contributions [11].

2.9. Chronological Timeline of Major Events

Early Foundations (1900-1945)

- 1900-1930s: Plastic surgeons develop principles of autografting and homografting.
- 1930s-1940s: Nomenclature of autograft, allograft, xenograft becomes standard.
- 1944-1947: Murray serves at Valley Forge General Hospital, intensively studying graft survival.

Translational Insight (1947-1954)

- 1947-1953: Murray joins Peter Bent Brigham Hospital; conducts research on graft rejection.
- Early 1950s: Skin grafts between identical twins show permanent acceptance.
- 1954: First successful identical-twin kidney transplant [2].

Expansion of Clinical Transplantation (1955-1963)

- 1955-1959: Trials of total body irradiation [6].
- 1959-1963: Introduction of azathioprine; increased graft survival in non-identical donors [7].

Establishing Ethical and Institutional Frameworks (1960-1969)

- 1962: Chairs the First International Conference on Human Kidney Transplantation.
- 1962: Helps establish the National Kidney Transplant Registry at the Brigham; becomes Medical Director.

- 1962-1968: Leads national and international efforts on transplant indications, donor safety, and recipient selection.
- 1968: Serves on the *Harvard Ad Hoc Committee on the Definition of Death*, establishing brain-death criteria; foundational for deceased-donor transplantation [9].

Consolidation of the Field (1964-1980s)

- 1960s-1970s: Kidney transplantation becomes accepted therapy.
- Murray leads innovations in craniofacial and reconstructive surgery.

Recognition and Legacy (1990-2012)

- 1990: Murray awarded the Nobel Prize in Physiology or Medicine [10].
- 2012: Murray dies at age 93, remembered as a pioneer of transplantation and reconstructive surgery.

3. Conclusions

Joseph E. Murray's career represents one of the most extraordinary arcs in surgical history: from burn reconstruction and graft biology to the establishment of organ transplantation as a therapeutic reality. His work is a powerful reminder that scientific innovation often emerges from careful clinical observation, intellectual curiosity, and the translational mindset that defines the surgeon-scientist.

Plastic surgery provided the biological insight and technical precision that made transplantation possible. Murray's legacy therefore belongs not only to transplant surgery but also to the broader surgical community—particularly plastic surgery, where the fundamental principles of grafting were first discovered. His work continues to influence modern immunology, medical ethics, and patient care, more than seventy years after the first skin grafts that inspired a revolution.

The immunologic principles underlying kidney transplantation were rooted in the pioneering work of Peter Medawar, whose studies of skin grafting during and after World War II demonstrated that homograft rejection was an immune-mediated phenomenon characterized by specificity and memory [3]. Medawar's observation that skin—highly antigenic due to its abundance of antigen-presenting cells—was rapidly rejected provided a model for understanding allograft immunity. Building on these insights, Joseph Murray translated this knowledge into clinical practice, recognizing that successful organ transplantation required overcoming similar immunologic barriers. This conceptual foundation culminated in the first successful human kidney transplant between identical twins in 1954, a milestone that validated Medawar's immunologic framework and ushered in the modern era of transplantation [2]. Medawar and Burnet were awarded the 1960 Nobel Prize in Physiology or Medicine for their discovery of acquired immunological tolerance [12]. Murray would later receive the same honor in 1990 for his clinical achievements in organ transplantation.

Conflicts of Interest

The author declares no conflicts of interest regarding the publication of this paper.

References

[1] Monaco, A.P. (2013) Joseph Edward Murray, M.D., 1919-2012: Pioneering Transplant and Reconstructive Plastic Surgeon and Scientist, Nobel Laureate, Humanitarian—An Appreciation. *Transplantation*, **95**, 903-907. https://doi.org/10.1097/tp.0b013e3182895cf2

[2] Merrill, J.P. (1956) Successful Homotransplantation of the Human Kidney between Identical Twins. *Journal of the American Medical Association*, **160**, 277-282. https://doi.org/10.1001/jama.1956.02960390027008

[3] Medawar, P.B. (1944) The Behavior and Fate of Skin Autografts and Skin Homografts in Rabbits: A Report to the War Wounds Committe of the Medical Research Council. *Journal of Anatomy*, **78**, 176-199.

[4] Cash, M.P., Dente, C.J. and Feliciano, D.V. (2005) Joseph E. Murray (1919-): Nobel Laureate, 1990. *Archives of Surgery*, **140**, 270-272. https://doi.org/10.1001/archsurg.140.3.270

[5] Watts, G. (2011) Joseph Murray: Innovative Surgeon and Pioneer of Transplantation. *The Lancet*, **377**, 987. https://doi.org/10.1016/s0140-6736(11)60375-9

[6] Murray, J.E., *et al.* (1960) Study on Transplantation Immunity after Total Body Irradiation: Clinical and Experimental Investigation. *Surgery*, **48**, 272-284.

[7] Murray, J.E., Merrill, J.P., Harrison, J.H., Wilson, R.E. and Dammin, G.J. (1963) Prolonged Survival of Human-Kidney Homografts by Immunosuppressive Drug Therapy. *New England Journal of Medicine*, **268**, 1315-1323. https://doi.org/10.1056/nejm196306132682401

[8] Elion, G.B., Singer, S. and Hitchings, G.H. (1954) Microbiological Effects of 6-Mercaptopurine. *Annals of the New York Academy of Sciences*, **60**, 200-206. https://doi.org/10.1111/j.1749-6632.1954.tb40009.x

[9] (1968) A Definition of Irreversible Coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. *JAMA*, **205**, 337-340. https://doi.org/10.1001/jama.1968.03140320031009

[10] Murray, J.E. (1990) The First Successful Organ Transplants in Man. *Journal of the American College of Surgeons*, **200**, 5-9.

[11] Adams, A.B., Goldstein, J., Garrett, C., Zhang, R., Patzer, R.E., Newell, K.A., *et al.* (2017) Belatacept Combined with Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. *American Journal of Transplantation*, **17**, 2922-2936. https://doi.org/10.1111/ajt.14353

[12] Nobel Prize in Physiology or Medicine 1960. https://www.nobelprize.org/prizes/medicine/1960/summary/